This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Sterol 14 Alpha-Demethylase Inhibitor development. The report ...

Endlyz Therapeutics has launched from stealth, unveiling its pipeline of small molecule modulators designed to restore lysosomal function in Parkinson’s disease (PD) and other neurodegenerative ...

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today participation in the following upcoming ...

CRISPR Therapeutics CRSP reported second-quarter results in line with our expectations, and its pipeline candidates are continuing to make progress. Collaboration revenue totaled $70 million ...

SER-155 has not yet achieved proof of concept but is the most promising asset in the pipeline. Dr_Microbe/iStock via Getty Images Seres Therapeutics (NASDAQ:MCRB) has successfully shepherded SER ...

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today ...

Nearly three years after launch, Versant Ventures spinout Pipeline Therapeutics is banking $80 million to push its lead neurodegenerative disease programs through the clinic. The funds will ...

AdoRx Therapeutics is pursuing the discovery of new therapeutics ... of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis ...

Johnson & Johnson is teaming up with AdoRx Therapeutics to develop lung cancer drugs. The deal gives J&J an exclusive option to research, develop and commercialize AdoRx antagonists. AdoRx ...

DUBLIN – Scottish startup Adorx Therapeutics Ltd. is the latest contender to tackle the knotty problem of immunosuppression in the tumor microenvironment through adenosine receptor inhibition. The ...

AdoRx Therapeutics, a UK based drug discovery company focused on the identification of new cancer therapeutics, today announced that it has closed an initial $10 million investment round financed by ...